Qiming U.S. Ventures Management’s HilleVax HLVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-372,615
| Closed | -$742K | – | 5 |
|
|
2025
Q2 | $742K | Hold |
372,615
| – | – | 3.14% | 5 |
|
|
2025
Q1 | $540K | Hold |
372,615
| – | – | 2.34% | 4 |
|
|
2024
Q4 | $771K | Sell |
372,615
-186,308
| -33% | -$350K | 1.51% | 5 |
|
|
2024
Q3 | $984K | Hold |
558,923
| – | – | 1.92% | 4 |
|
|
2024
Q2 | $8.08M | Hold |
558,923
| – | – | 15.36% | 4 |
|
|
2024
Q1 | $9.29M | Hold |
558,923
| – | – | 10.36% | 4 |
|
|
2023
Q4 | $8.97M | Hold |
558,923
| – | – | 8.21% | 4 |
|
|
2023
Q3 | $7.52M | Hold |
558,923
| – | – | 9.98% | 4 |
|
|
2023
Q2 | $9.61M | Hold |
558,923
| – | – | 10.1% | 4 |
|
|
2023
Q1 | $9.24M | Hold |
558,923
| – | – | 11.18% | 4 |
|
|
2022
Q4 | $9.35M | Hold |
558,923
| – | – | 12.37% | 3 |
|
|
2022
Q3 | $9.55M | Hold |
558,923
| – | – | 13.87% | 3 |
|
|
2022
Q2 | $6.11M | Buy |
+558,923
| New | +$6.64M | 8.48% | 6 |
|
Qiming U.S. Ventures Management's HLVX Position: Q3 2025 in Review
Qiming U.S. Ventures Management sold out of HilleVax (HLVX) in Q3 2025, closing a stake of 372,615 shares — an estimated $742K sold.
Qiming U.S. Ventures Management first reported a position in HLVX in Q2 2022 and held it in 13 quarters. The position peaked at $9.61M in Q2 2023. 1 fund tracked by Wall St. Rank holds HLVX as of Q3 2025.
- Qiming U.S. Ventures Management reported no remaining HilleVax position as of Q3 2025 after selling out during the quarter.
- Qiming U.S. Ventures Management sold 372,615 HilleVax shares in Q3 2025, an estimated $742K.
- Qiming U.S. Ventures Management first reported a position in HilleVax in Q2 2022 and held it in 13 quarters.
- Qiming U.S. Ventures Management's HilleVax position peaked at $9.61M in Q2 2023.
- 1 fund tracked by Wall St. Rank held HilleVax as of Q3 2025.
Based on Qiming U.S. Ventures Management's 13F filing for Q3 2025, filed 10 Nov 2025.